Immune Pharmaceuticals Inc - ESG Rating & Company Profile powered by AI
Scroll down to the bottom of the webpage for potential risks for Immune Pharmaceuticals Inc based on sector, geography and marketcap. If you work at Immune Pharmaceuticals Inc and you would like to licence your Sustainability aseessment, please contact us. This page contains a free E,S&G report for Immune Pharmaceuticals Inc.
Immune Pharmaceuticals Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 0.0; made up of an environmental score of 0.0, social score of 0.0 and governance score of 0.0.
0.0
Low ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Novartis AG | 9.2 | High |
| 2 | Daiichi Sankyo Co Ltd | 8.9 | High |
| ... | ... | ... | |
| 2747 | Aphria Inc | 0.3 | Low |
| 2747 | Sichuan Languang Development Co Ltd | 0.3 | Low |
| 2749 | Immune Pharmaceuticals Inc | 0.0 | Low |
| 2749 | Alpha Group Industries Inc | 0.0 | Low |
| 2749 | BNC Korea Co Ltd (Pre-Merger) | 0.0 | Low |
| 2749 | Xynomic Pharmaceuticals Holdings Inc | 0.0 | Low |
| 2749 | Zyden Gentec Ltd | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Immune Pharmaceuticals Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Immune Pharmaceuticals Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Immune Pharmaceuticals Inc report the average age of the workforce?
Sign up for free to unlockDoes Immune Pharmaceuticals Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Immune Pharmaceuticals Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Immune Pharmaceuticals Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Immune Pharmaceuticals Inc offer flexible work?
Sign up for free to unlockDoes Immune Pharmaceuticals Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Immune Pharmaceuticals Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Immune Pharmaceuticals Inc conduct supply chain audits?
Sign up for free to unlockDoes Immune Pharmaceuticals Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Immune Pharmaceuticals Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Immune Pharmaceuticals Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Immune Pharmaceuticals Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Immune Pharmaceuticals Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Immune Pharmaceuticals Inc disclose water use targets?
Sign up for free to unlockDoes Immune Pharmaceuticals Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Immune Pharmaceuticals Inc have a product recall in the last two years?
Sign up for free to unlockDoes Immune Pharmaceuticals Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Immune Pharmaceuticals Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Immune Pharmaceuticals Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Immune Pharmaceuticals Inc disclose parental leave metrics?
Sign up for free to unlockDoes Immune Pharmaceuticals Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Immune Pharmaceuticals Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Immune Pharmaceuticals Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Immune Pharmaceuticals Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Immune Pharmaceuticals Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Immune Pharmaceuticals Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Immune Pharmaceuticals Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Immune Pharmaceuticals Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Immune Pharmaceuticals Inc disclose its waste policy?
Sign up for free to unlockDoes Immune Pharmaceuticals Inc report according to TCFD requirements?
Sign up for free to unlockDoes Immune Pharmaceuticals Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Immune Pharmaceuticals Inc disclose energy use targets?
Sign up for free to unlockDoes Immune Pharmaceuticals Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Immune Pharmaceuticals Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Immune Pharmaceuticals Inc
These potential risks are based on the size, segment and geographies of the company.
Immune Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of various therapeutic agents for the treatment of immunologic and inflammatory diseases. The company's lead product candidate is bertilimumab, a human antibody, which is in Phase II clinical trials that targets eotaxin-1 for the treatment of bullous pemphigoid and ulcerative colitis. It is also developing NanoCyclo, a nano-encapsulated formulation of cyclosporine-A, which is in late stage preclinical development for atopic dermatitis and psoriasis. In addition, the company's pain products include AmiKet and AmiKet Nano, a topical analgesic cream containing amitriptyline and ketamine for the treatment of postherpetic neuralgia and diabetic peripheral neuropathy. Further, its oncology portfolio comprises Ceplene, for the maintenance of remission in patients with acute myeloid leukemia in combination with interleukin-2; Azixa and crolibulin that are clinical-stage vascular disrupting agents; NanomAbs, a nanotechnology combination platform; and bispecific antibody platform. Immune Pharmaceuticals, Inc. was founded in 2010 and is based in Fort Lee, New Jersey. On April 2, 2020, the voluntary petition of Immune Pharmaceuticals, Inc. along with its affiliates, for reorganization under Chapter 11 was converted to Chapter 7. It had filed for Chapter 11 bankruptcy on February 17, 2020.